![Michael MacLean](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael MacLean
Directeur/Bestuurslid bij
CAMP4 THERAPEUTICS CORPORATION
Vermogen: 418 691 $ op 30-06-2026
Profiel
Michael F.
MacLean is an Independent Director at CAMP4 Therapeutics Corp.
and.
Research Alliance Corp.
III, both positions starting in 2026.
Former roles include Managing Director at Huron Consulting Group, Inc.; Independent Director at Verve Therapeutics, Inc. from 2021 to 2025; Chief Accounting Officer, SVP-Finance & Controller at Biogen, Inc. from 2006 to 2010; Chief Financial Officer-North America Division at Iron Mountain, Inc. from 2014 to 2015; Partner at Arthur Andersen LLP from 1999 to 2002; Chief Accounting Officer, SVP & Controller at Biogen Idec New Ventures, Inc.; Chief Financial Officer & Executive Vice President at PureTech Health Plc from 2015 to 2017; Chief Financial & Accounting Officer at Akcea Therapeutics, Inc. from 2017 to 2020; Chief Financial & Business Officer at Avidity Biosciences, Inc. from 2022 to 2026; and Partner at KPMG International Ltd. Education includes an undergraduate degree from Boston College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
2,96% | 20-05-2026 | 39.130 ( 2,96% ) | 418 691 $ | 30-06-2026 |
| 01-04-2026 | 0 ( -.--% ) | - $ | 30-06-2026 |
Actieve functies van Michael MacLean
| Bedrijven | Functie | Begin |
|---|---|---|
| CAMP4 THERAPEUTICS CORPORATION | Directeur/Bestuurslid | 01-04-2026 |
Eerdere bekende functies van Michael MacLean
| Bedrijven | Functie | Einde |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Financieel Directeur/CFO | 27-02-2026 |
| VERE THER | Directeur/Bestuurslid | 25-07-2025 |
| AKCEA THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-04-2020 |
| PURETECH HEALTH PLC | Financieel Directeur/CFO | 01-08-2017 |
| IRON MOUNTAIN INCORPORATED | Comptroller/Controller/Auditor | 01-07-2014 |
Opleiding van Michael MacLean
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
12
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 12 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Huron Consulting Group, Inc.
 Huron Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides healthcare, business advisory and education services | Commercial Services |
Avidity Biosciences, Inc.
 Avidity Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that provides research and development, administrative & investment services | Health Technology |
Iron Mountain, Inc.
 Iron Mountain, Inc. Real Estate Investment TrustsFinance Functions as a real estate investment trust which provides records and information management storage solutions | Finance |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
PureTech Health Plc
 PureTech Health Plc BiotechnologyHealth Technology Engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy and autoimmune | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Verve Therapeutics, Inc.
 Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
KPMG International Ltd.
 KPMG International Ltd. Miscellaneous Commercial ServicesCommercial Services Provides audit, tax and advisory services | Commercial Services |
Kies MarketScreener 
